<DOC>
	<DOCNO>NCT01279798</DOCNO>
	<brief_summary>This expand access protocol design make Lucanix® available subject advance non-small cell lung cancer ( NSCLC ) eligible Phase III Protocol , NR001-03 . A total 45 patient enrol study .</brief_summary>
	<brief_title>Expanded Access Multicenter Study Lucanix® ( Belagenpumatucel-L )</brief_title>
	<detailed_description>The primary objective study increase overall survival study subject provide expanded access Lucanix . Overall survival progression-free survival compare historical control . The secondary objective study : - Evaluate best overall tumor response . - Evaluate progression-free survival ( PFS ) . - Evaluate treatment toxicity .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Signed informed consent ≥ 18 year Histological confirm noncurable stage III IV NSCLC . Must complete least one ( 1 ) regimen anticancer therapy . Following frontline therapy , subject must observe follow wash period : Subjects stable disease well must receive last anticancer therapy less five month prior enrollment . Subjects progressive disease must receive last anticancer therapy least one ( 1 ) month prior enrollment . All subject receive two ( 2 ) regimens therapy must receive last anticancer therapy least one ( 1 ) month prior enrollment . Performance status ( ECOG ) ≤ 2 Absolute granulocyte count ≥ 1,500/mm3 Platelet count ≥ 100,000/mm3 Total Bilirubin ≤ 2× Upper Limit Normal AST ALT ≤ 2× Upper Limit Normal Creatinine ≤ 2× Upper Limit Normal Negative pregnancy test woman childbearing potential . Concurrent systemic steroid &gt; 2 mg prednisone/day Prior splenectomy Any chemotherapy , steroid therapy , investigational anticancer agent within 4 week study entry . Subjects receive prior monotherapy Lucanix . Symptomatic brain metastasis unless treat stable ≥ 2 month Known HIV positivity Serious nonmalignant disease ( e.g. , congestive heart failure , active uncontrolled bacterial , viral , fungal infection ) , condition , opinion investigator would compromise protocol objective . Prior malignancy ( exclude nonmelanoma carcinomas skin ) unless remission ≥ 2 year History psychiatric disorder would impede adherence protocol Pregnant nursing woman refusal practice contraception reproductive potential</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Lung Cancer</keyword>
	<keyword>NSCLC</keyword>
	<keyword>stage III IV NSCLC</keyword>
</DOC>